| A Multistrain Probiotic in Patients With Irritable Bowel Syndrome With Predominant Constipation (NCT04997057) | CEN Biotech | 2022-01-04 |
| IBS-C Questionnaire Study (NCT04968652) | AstraZeneca | 2021-11-01 |
| Safety and Efficacy of Non-alcoholic Beverage Based on Kombucha in Patients With Constipations (NCT05164861) | Vasily Isakov | 2021-11-01 |
| Effect of Tai Chi as Treatment for IBS-C (NCT04132804) | Massachusetts General Hospital | 2020-07-21 |
| A Non-Interventional Pilot Study to Explore the Role of Gut Flora in IBS (NCT04214470) | ProgenaBiome | 2020-03-02 |
| Long-term Safety of Linaclotide in Pediatric Participants With FC or IBS-C (NCT04166058) | AbbVie | 2019-11-19 |
| Efficacy and Safety of SYN-010 in IBS-C (NCT03763175) | Cedars-Sinai Medical Center | 2018-12-24 |
| Efficacy and Safety of Plecanatide in Children 6 to <18 Years With Irritable Bowel Syndrome With Constipation (IBS-C) (NCT03596905) | Bausch Health Americas, Inc. | 2018-06-30 |
| Efficacy and Safety of a Food Supplement With Standardized Menthol, Limonene, and Gingerol Content in Patients With Irritable Bowel Syndrome (NCT04484467) | Federal Stare Budgetary Scientific Institution, Mental Health Research Center | 2018-02-09 |
| An Evaluation of Cultured Milk Drink on Immune Status of Patients With Irritable Bowel Syndrome: Constipation Predominant (NCT04647045) | National University of Malaysia | 2017-05-02 |
| The Effect of CSP01 on Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation (NCT03054506) | Massachusetts General Hospital | 2017-03-07 |
| A Safety and Efficacy Study of a Range of Linaclotide Doses Administered Orally to Children Ages 7-17 Years, With Irritable Bowel Syndrome With Constipation (NCT02559817) | Forest Laboratories | 2015-11-01 |
| An Open-Label, Long-term Study to Assess the Immunogenicity of LINZESS® (Linaclotide) Administered Orally to Adult Participants With Irritable Bowel Syndrome With Constipation or Chronic Idiopathic Constipation (NCT02590432) | Forest Laboratories | 2015-11-01 |
| Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C) (NCT02559206) | Ironwood Pharmaceuticals, Inc. | 2015-10-22 |
| An Open-Label, Long-Term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation (NCT00765999) | Forest Laboratories | 2008-10-31 |
| An Open-label, Long-term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation (NCT00730171) | Ironwood Pharmaceuticals, Inc. | 2008-09-01 |
| Randomized, Double-blind, Dose-range-finding, Phase 2 Study of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation (IBS-C) (NCT00460811) | Ironwood Pharmaceuticals, Inc. | 2007-04-01 |
| A Study to Evaluate the Safety, Tolerability and Pharmacodynamics of DDP733 for IBS-c (NCT00215566) | Dynogen Pharmaceuticals | 2005-09-01 |
| Efficacy and Safety of Lubiprostone in Patients With Irritable Bowel Syndrome With Constipation (NCT00380250) | Sucampo Pharma Americas, LLC | 2005-05-01 |
| A Treatment Investigational New Drug (tIND) Program of Tegaserod in Women With Irritable Bowel Syndrome With Constipation or With Chronic Idiopathic Constipation (NCT00511771) | Novartis | |